Laura J. Hamill

Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences

Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. She has successfully launched numerous breakthrough therapies as a global, regional and country leader. Her areas of therapeutic expertise include inflammation, oncology, gene therapy, nephrology, osteoporosis, cardiovascular disease, HIV, hepatology, GI and anti-infectives. Most recently, Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, where she was involved in the strategic direction and long-term planning of the organization. Previously, Ms. Hamill held a number of executive roles at Amgen, culminating with Senior Vice President and General Manager where she led ~$20B in U.S. commercial operations. Her prior experience at Amgen included US and international roles including Senior Vice President and Regional General Manager for the Intercontinental Region, Vice President/General Manager U.S. Inflammation Business Unit, VP International Marketing and Business Operations in Switzerland, and VP/GM U.S. Corporate Accounts/ Reimbursement and Access. Prior to Amgen, Ms. Hamill held positions at Hoffmann-La Roche Ltd. and Klemtner Advertising. Ms. Hamill served as the Pharma Chairperson for the Latin America Regional Committee while leading Amgen’s Intercontinental Region. Laura served as the Chairperson of Amgen’s Senior Women’s Leadership Council and was an active member of the Women Business Leaders of the U.S. Health Care Industry Foundation. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona.